News
Check out the posts below to learn the latest updates on our progress
- April 17 2023In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR-T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue in NSG-SGM3 CD34+ humanized miceAACR 2023
- April 17 2023EXUMA Biotech Presents Early Clinical and Translational Findings from Solid Tumor Cell Therapy and In Vivo CAR Engineering Research at the AACR Annual Meeting 2023PRNewswire
- October 4 2022Dr. Sid Kerkar speaks with CGT Live about how EXUMA’s TaNK platforms aim to make CAR therapy safer and faster through novel lentivector engineeringCGT Live
- September 16 2022EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR SummitPR Newswire
- September 15 2022In vivo generation of tumor-metabolism-regulated HER2-specific CAR+ cells eradicate established HER2+ gastric carcinomas with the novel subcutaneous route of administration of CD3-directed lentivector-loaded lymphocytes.
- September 8 2022EXUMA Biotech to Participate in the Upcoming Baird Global Healthcare Investor ConferencePR Newswire
- July 6 2022EXUMA Biotech Announces Participation in the In Vivo Engineering of Therapeutic Cells SummitPRNewswire
- June 21 2022Dr. Sid Kerkar talks to OncologyTube about EXUMA’s rPOC SC and in vivo GCAR programsOncologyTube
- April 11 2022Dr. Sid Kerkar talks to VJHemOnc at AACR 2022 about rPOC SC
VJHemOnc - April 8 2022In vivo delivery of a novel CD3-targeted Lentiviral Vector generates CD19 CAR-T cells in two different humanized mouse models and results in complete B cell depletion
AACR 2022